Denosumab (Prolia) injection: A new approach to the treatment of women with postmenopausal osteoporosis

P and T

Volumn 35, Issue 10, 2010, Pages 553-559

  Green, Wendy ^a  

^a HARRIS COUNTY HOSPITAL DISTRICT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BENZODIAZEPINE; CALCITONIN; CALCITONIN SALMON; DENOSUMAB; IBANDRONIC ACID; PLACEBO; PROLIA; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; UNCLASSIFIED DRUG;

ARTHRALGIA; CELLULITIS; CLINICAL TRIAL; DRUG COST; DRUG DOSE ESCALATION; DRUG INDICATION; DRUG MECHANISM; DRUG WITHDRAWAL; DYSPEPSIA; ECZEMA; ERYSIPELAS; HUMAN; INFECTION; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; OSTEOPOROSIS; POSTMENOPAUSE; RESPIRATORY TRACT INFECTION; REVIEW; RHINOPHARYNGITIS; RISK FACTOR;

EID: 78149405244     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Aubin JE, Bonnelye E. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int 2000;11:905-913.
2. Sattler A, Schoppet M, et al. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif Tissue Int 2004;74:103-106.
3. Vega D, Maalouf N, Sakhaee K. The role of receptor activator of nuclear factor-κB (RANK)/RANK ligand/osteoprotegerin: Clinical implications. J Clin Endocrinol Metab 2007;92:4514-4521.
4. Miller P. Denosumab: Anti-RANKL antibody. Curr Osteoporos Rep 2009;7:18-22.
5. O'Connell MB, Seaton TL. Osteoporosis and osteomalacia. In: DiPiro JT, Talbert RL, Yee GC, eds. Pharmacotherapy: A Pathophysiologic Approach, 6th ed. New York: McGraw-Hill; 2005.
6. World Health Organization. WHO Scientific Group on the Assess ment of Osteoporosis at Primary Health Care Level. Available at: www.who.int/chp/topics/ Osteoporosis.pdf. Accessed July 1, 2010.
7. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Available at: www.nof.org/professionals/pdfs/NOF- ClinicianGuide2009-v7.pdf.Accessed July 2, 2010.
8. Cummings S, San Martin J, McClung M, et al. Denosumab for the prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361: 756-765.
9. Bone Health and Osteoporosis: A Report of the Surgeon General. Office of the Surgeon General, U.S. Department of Health and Human Services. Available at: www.surgeongeneral.gov/library/bonehealth/preface.html. Accessed August 30, 2010.
10. Third National Health and Nutrition Examination Survey (NHANES III). U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, Hyattsville, Md. Available at: www.cdc.gov/nchs/products/elecprods/subject/nhanes3.htm. Accessed August 27, 2010.
11. U.S. Department of Health & Human Services. Healthy People 2010. Available at: www.healthypeople.gov. Accessed July 2, 2010.
12. U.S. Department of Health & Human Services. Proposed Healthy People 2020 Objectives. Available at: www.healthypeople.gov/hp2020/Objectives/ TopicAreas.aspx. Accessed July 2, 2010.
13. Prolia (denosumab), prescribing information. Thousand Oaks, Calif.: Amgen; June 2010 (revised). Available at: www.prolia.com. Accessed June 14, 2010.
14. McClung M, Lewiecki M, Cohen S, et al. Denosumab in postmenopausal women with low bone density. N Engl J Med 2006;354:821-831.
15. Bone H, Bolognese M, Yuen C, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008;93:2149-2157.
16. Kendler D, Roux C, Benhamou C, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010; 25:72-81.
17. Lewiecki E, Miller P, McClung M, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 2007;22:1832-1841.
18. Reid IR. Osteonecrosis of the jaw: Who gets it, and why. Bone 2008;44:4-10.
19. Khosla S, Burr D, Cauley J, et al. Bis phosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-1491.
20. American Association of Oral and Maxillofacial Surgeons. Position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-376.
21. Durie B, Katz M. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99-100.
22. Morris & Dickson. Average wholesale price outpatient cost data. Available at: www.morrisdickson.com. Accessed June 22, 2010.
23. National Institutes of Health. Available at: www.clinicaltrials.gov; www.nih.gov. Accessed June 24, 2010.
24. Bekker P, Holloway D, Rasmussen A, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004;19:1059-1066.